All In Biotech

Drug Trial Radar · NCT00802672

Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% for the Treatment of Tinea Pedis

A Double-blind, Randomized, Parallel-group, Vehicle-controlled, Multi-center Study to Evaluate the Safety and Clinical Equivalence of a Generic Ciclopirox Olamine Cream to Ciclopirox Cream 0.77% in the Treatment of Tinea Pedis

Last checked: Nov 20, 2026Latest source record: Oct 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 561 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

561

Actual

Start

Dec 2003

Primary completion

May 2004

Study completion May 2004

Sponsor

Lead sponsor
Padagis LLCIndustry
Sponsor type
Industry
First posted
Dec 5, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this study were to demonstrate comparable safety and efficacy of Ciclopirox Olamine Cream (Test Product) and Ciclopirox Cream 0.77% (Reference Product) in the treatment of subjects with tinea pedis, and to show the superiority of the active treatments over that of the vehicle.

Conditions

  • Tinea Pedis

Interventions

  • Ciclopirox Olamine CreamDrug

    topical cream

  • Loprox Cream 0.77%Drug

    topical cream

  • PlaceboDrug

    topical cream

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects in Each Treatment Group With Therapeutic SuccessTime frame: 6 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.